BioSpace News Archive

Business

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.

May 17, 2022
·
8 min read
Business

Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.

May 17, 2022
·
1 min read
Genetown

Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022

Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022.

May 17, 2022
·
3 min read
Business

Glympse Appoints Jonathan Wilde, Ph.D., as Chief Scientific Officer to Advance Biosensor Assay Platform

Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, announced the appointment of Jonathan Wilde, Ph.D., as Chief Scientific Officer.

May 17, 2022
·
2 min read
Business

Delfi Diagnostics Enters into Broad Research Agreement with Top U.S. Cancer Center

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center.

May 17, 2022
·
2 min read
Biotech Beach

Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference

Aethlon Medical, Inc., announced that it will be presenting at the H.C. Wainwright Global Investment Conference.

May 17, 2022
·
4 min read
Drug Development

HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2

Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with the strong CYP2D6 inhibitor, paroxetine.

May 17, 2022
·
2 min read
Pharm Country

Iveric Bio to Present at the UBS Global Healthcare Conference 2022

Iveric Bio to Present at the UBS Global Healthcare Conference 2022.

May 17, 2022
·
2 min read
Biotech Beach

MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022.

May 17, 2022
·
4 min read
BioMidwest

LGM Pharma’s Unique Mix of API Sourcing and CDMO Services Is Fueling Robust Growth

LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, reported that its unique mix of active pharmaceutical ingredient sourcing and contract development and manufacturing services is helping to drive robust growth.

May 17, 2022
·
4 min read